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Tuberous Sclerosis Complex Gene Products, Tuberin
and Hamartin, Control mTOR Signaling by Acting as
a GTPase-Activating Protein Complex toward Rheb
eyes, and skin (for review see [1]). TSC mainly occurs
through the loss of heterozygosity of the TSC1 or TSC2
gene, encoding for Hamartin and Tuberin protein, re-
spectively [2, 3]. Tuberin and Hamartin form a hetero-
dimer that inhibits cell growth and proliferation [3–6]. As
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Hamartin, a 130 kDa protein, contains a putative trans-Boston, Massachusetts
membrane domain, implying that it is membrane bound,
as well as two coiled-coil domains that are necessary
for its association with Tuberin [7, 8]. Hamartin alsoSummary
interacts with the ezrin-radixin-moesin family member
proteins and activates the small-GTP binding proteinBackground: Tuberous Sclerosis Complex (TSC) is a
genetic disorder that occurs through the loss of hetero- Rho [9], suggesting that Hamartin regulates cell adhe-
sion. Hamartin’s binding partner, Tuberin (198 kDa), con-zygosity of either TSC1 or TSC2, which encode Hamartin
or Tuberin, respectively. Tuberin and Hamartin form a tains a region of limited homology to the catalytic do-
main of Rap1GAP at its C terminus. Tuberin has beentumor suppressor heterodimer that inhibits the mamma-
lian target of rapamycin (mTOR) nutrient signaling input, reported to weakly stimulate GTP hydrolysis of Rap1a
and Rab5 but not of Rap2, Ras, Rab3a, Rab6, Rac, orbut how this occurs is unclear.
Results: We show that the small G protein Rheb (Ras Rho in vitro [10, 11]. However, Tuberin has been sug-
gested to function as a RhoGAP in vivo [12].homolog enriched in brain) is a molecular target of TSC1/
TSC2 that regulates mTOR signaling. Overexpression of Both Drosophila and mammalian studies demon-
strated that Tuberin/Hamartin act upstream of S6K1 andRheb activates 40S ribosomal protein S6 kinase 1 (S6K1)
but not p90 ribosomal S6 kinase 1 (RSK1) or Akt. Further- downstream of Akt (also referred to as protein kinase
B (PKB)) within the PI3K signaling pathway [13–16]. Amore, Rheb induces phosphorylation of eukaryotic initi-
ation factor 4E binding protein 1 (4E-BP1) and causes number of reports that followed revealed that Tuberin/
Hamartin inhibited the nutrient signaling input to mTOR4E-BP1 to dissociate from eIF4E. This dissociation is
completely sensitive to rapamycin (an mTOR inhibitor) [17–19]. mTOR is a known regulator of both cell growth
and cell proliferation, which are coordinated by at leastbut not wortmannin (a phosphoinositide 3-kinase [PI3K]
inhibitor). Rheb also activates S6K1 during amino acid two downstream mTOR targets, S6K1 and 4E-BP1 (also
known as PHAS-I) [20]. Loss of either Hamartin or Tu-insufficiency via a rapamycin-sensitive mechanism,
suggesting that Rheb participates in nutrient signaling berin expression within cells resulted in constitutive
S6K1 activation in the absence of amino acids [18].through mTOR. Moreover, Rheb does not activate a
S6K1 mutant that is unresponsive to mTOR-mediated Furthermore, overexpression of Hamartin and Tuberin
blocked S6K1 activation upon the readdition of aminosignals, confirming that Rheb functions upstream of
mTOR. Overexpression of the Tuberin-Hamartin hetero- acids to nutrient-starved cells [18, 19].
It is unclear how mTOR senses nutrients, but it is likelydimer inhibits Rheb-mediated S6K1 activation, sug-
gesting that Tuberin functions as a Rheb GTPase acti- that it senses intracellular rather than extracellular amino
acids through an unknown mechanism [21]. The mecha-vating protein (GAP). Supporting this notion, TSC
patient-derived Tuberin GAP domain mutants were un- nism by which the Tuberin/Hamartin heterodimer inhib-
able to inactivate Rheb in vivo. Moreover, in vitro studies its the nutrient-mediated input to mTOR is currently un-
reveal that Tuberin, when associated with Hamartin, acts defined. Mutational analysis of TSC2 from TSC patients
as a Rheb GTPase-activating protein. Finally, we show suggested that the GAP domain of Tuberin is critical for
that membrane localization of Rheb is important for its its function [22]. For instance, common TSC patient-
biological activity because a farnesylation-defective derived TSC2 mutations result in the loss of the GAP
mutant of Rheb stimulated S6K1 activation less effi- domain of Tuberin through C-terminal truncations,
ciently. whereas some of the more infrequent TSC2 point muta-
Conclusions: We show that Rheb acts as a novel medi- tions are clustered within the GAP domain [22]. It is,
ator of the nutrient signaling input to mTOR and is the therefore, possible that Tuberin possesses GAP activity
molecular target of TSC1 and TSC2 within mammalian toward a small G protein, which would normally enhance
cells. mTOR signaling when in an active GTP bound state
during conditions of nutrient sufficiency.
Introduction Rheb (Ras homolog enriched in brain) is a likely small
G protein candidate that may be involved during nutrient
TSC is a human genetic syndrome characterized by the signaling. The loss of Rheb in yeast was shown to mimic
formation of benign tumors in the brain, heart, kidneys, nutrient starvation by causing G0/G1 arrest [23]. Deletion
of Rheb in S. cerevisiae also resulted in the increased
uptake of both arginine and lysine [24]. Rheb is related*Correspondence: john_blenis@hms.harvard.edu
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to the Ras, Rap, and Ral subfamilies [25] and is farnesy- cally inhibit MEK (as observed by reduced ERK1 and
ERK2 phosphorylation and RSK1 activity). These find-lated within a C-terminal CaaX motif (a is an aliphatic
amino acid, and X is a serine, alanine, glutamine, cys- ings suggest that Rheb does not function upstream of
either PI3K/Akt or ERK/RSK1 signaling pathways.teine or methionine) [26]. Rheb has also been shown to
cooperate synergistically with Raf-1 to transform
NIH3T3 cells [26] and to bind and inhibit B-Raf kinase Rheb Induces 4E-BP1 Phosphorylation,
[27]. In this study we reveal that Rheb enhances mTOR- which Is Rapamycin Sensitive
mediated signaling toward S6K1 and 4E-BP1. Overex- and Wortmannin Insensitive
pression of Rheb was sufficient to enhance S6K1 activity Because Rheb enhanced the activity of S6K1, a down-
in the absence of nutrients, indicating that Rheb may stream component of mTOR, we investigated the effects
be a component of the nutrient-sensing machinery of of Rheb-mediated signaling on 4E-BP1, another down-
mTOR. We also report that Tuberin-Hamartin hetero- stream component of mTOR. Dephosphorylated species
dimers inhibit Rheb-induced mTOR signaling, which re- of 4E-BP1 bind to and inhibit eIF4E-driven cap-dependent
quires an intact GAP domain of Tuberin. Furthermore, translation (for review see [31]). Phosphorylation of 4E-
we show that Tuberin when associated with Hamartin BP1 at multiple Ser/Thr-Pro residues upon mitogenic
functions as a GAP toward Rheb. stimulation leads to the release of 4E-BP1 from eIF4E,
which is blocked by both rapamycin and nutrient starva-
tion. Three different phosphorylated species of 4E-BP1Results
resolve on SDS-PAGE, with - and -isoforms being the
most and least phosphorylated species, respectively.Rheb Overexpression Activates S6K1
To determine whether Rheb activates mTOR- or PI3K-but Not Akt or RSK1
mediated signaling, we coexpressed Rheb with hemag-To examine whether Rheb overexpression could modu-
glutinin (HA)-tagged 4E-BP1 in the presence of eitherlate S6K1 activity, we coexpressed S6K1 with Rheb at
rapamycin or wortmannin to inhibit mTOR or PI3K, re-two different expression levels in HEK293E cells and
spectively (Figure 2A). Insulin-induced Akt phosphoryla-assayed for kinase activity by using GST-S6 as a sub-
tion on Ser473 was blocked by wortmannin, revealingstrate (Figure 1A). Coexpression of Rheb at either ex-
that the concentration of wortmannin used in this studypression level significantly increased the basal and insu-
efficiently inhibited PI3K-mediated signaling. Insulin-lin-stimulated activity of S6K1. Higher levels of Rheb
induced phosphorylation of 4E-BP1 was also blockedexpression enhanced the basal and insulin-stimulated
by wortmannin, as observed by the reduced mobilityactivity of S6K1 by 5.6- and 1.7-fold, respectively, and
shift of 4E-BP1 to the less-phosphorylated isoforms andthis activity level was more potent than the S6K1 activity
by decreased Ser65 phosphorylation. Rheb overexpres-observed in the presence of lower levels of Rheb protein.
sion within serum-starved cells potently enhanced 4E-These results indicate that Rheb activates signaling cas-
BP1 phosphorylation, which was still sensitive to rapa-cades that result in S6K1 activation.
mycin. In contrast, treatment of cells with wortmanninGiven that the activity of S6K1 is enhanced upon cell
was modestly effective at reducing 4E-BP1 phosphory-signaling through mTOR- [28], PI3K- (for review see [29]),
lation upon Rheb overexpression, indicating that PI3Kand mitogen-activated protein kinase (MAPK)- and pro-
signaling is not essential for Rheb-induced 4E-BP1tein kinase C (PKC)-mediated pathways [30], we deter-
phosphorylation. These data suggest that Rheb signalsmined which signaling pathway was activated upon
by using an mTOR-dependent rather than a PI3K-depen-Rheb overexpression. To investigate PI3K-mediated
dent mechanism. Rheb-induced 4E-BP1 phosphoryla-signaling, we coexpressed Rheb with Akt, a downstream
tion should promote the release of 4E-BP1 from eIF4E.target of PI3K, within HEK293E cells and assayed for
To confirm this, we purified endogenous eIF4E onkinase activity by using GST-tagged glycogen synthase
m7GTP-Sepharose, which mimics the cap-structurekinase-3 (GSK-3) as a substrate (Figure 1B). Whereas
found at the extreme 5 terminus of most cytoplasmicEGF stimulation led to a 4-fold increase in Akt activity,
mRNAs, and examined how much HA-tagged 4E-BP1Rheb overexpression did not enhance basal or EGF-
was bound to eIF4E (Figure 2B). As expected, 4E-BP1stimulated Akt activity. In contrast, Rheb potently acti-
was released from eIF4E upon Rheb overexpression,vated S6K1 by 11-fold when assayed in parallel. We
implying that Rheb activates cap-dependent translation.used wortmannin as a control to show that we were
specifically measuring PI3K-mediated activation of Akt
upon stimulation with EGF. To examine whether Rheb Rheb Overexpression Enhances Nutrient-
Mediated Signaling toward S6K1enhanced MAPK-mediated signaling, we coexpressed
Rheb with RSK1, a known downstream signaling com- The above data implies that Rheb may modulate mTOR
signaling. Given that the loss of Rheb in yeast mimickedponent of MAPK, within HEK293E cells (Figure 1C). Al-
though EGF stimulation led to a 12-fold increase in RSK1 nutrient starvation [23], Rheb overexpression may pro-
mote mTOR signaling through a nutrient-regulated sig-activity, Rheb did not augment the basal or EGF-induced
activation of RSK1 assayed with GST-S6 as a substrate. naling pathway. To address this possibility, we investi-
gated whether Rheb promotes S6K1 activation in theIn contrast, Rheb overexpression drastically increased
S6K1 activity when assayed in parallel. To inhibit activa- absence of amino acids (Figure 3). During conditions of
amino acid withdrawal, Rheb overexpression potentlytion of ERK (extracellular signal-regulated kinase)
through MEK (MAPK/ERK-kinase)-mediated signaling, activated S6K1 (Figure 3, lane 6), which was completely
blocked by rapamycin (Figure 3, lane 7) but only partiallywe treated cells with the U0126 compound to specifi-
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Figure 1. Rheb Overexpression Activates S6K1 and Not RSK1 or Akt
(A) HEK293E cells coexpressing low () or high () levels of Rheb, where indicated, with HA-tagged S6K1 were serum starved. The cells
were pretreated with 25 nM rapamycin for 30 min and stimulated with 100 nM insulin for 30 min, where indicated. The total levels of Rheb
and S6K1 are shown. S6K1 activity was measured by incorporation of 32P label into GST-S6 substrate, as described in the Experimental
Procedures, and was assessed by autoradiograph.
(B) HEK293E cells transiently transfected with plasmids expressing Rheb and HA-tagged Akt and S6K1, where indicated, were serum starved.
These cells were pretreated with 100 nM wortmannin (Wort) for 30 min before being stimulated with 25 ng/ml EGF for 10 min, where stated.
Akt and S6K1 activity was measured as described in the Experimental Procedures. The total levels of Akt, Rheb, and S6K1 and Akt phosphoryla-
tion on Ser473 are shown.
(C) HEK293E cells expressing Rheb and HA-tagged RSK1 and S6K1, where indicated, were serum starved. These cells were pretreated with
2.5 M U0126 for 30 min before being stimulated with 25 ng/ml EGF for 10 min, where indicated. RSK1 and S6K1 activity was measured as
described in the Experimental Procedures. The total levels of Erk1/2, Rheb, RSK1, and S6K1 are shown as well as Erk1/2 phosphorylation.
Fold activation of S6K1, Akt, and RSK1 from untreated conditions is graphed, where applicable.
inhibited by wortmannin (Figure 3, lane 8). Importantly, of nutrients through mTOR rather than PI3K-mediated
signaling. Therefore, it is likely that Rheb enhances nutri-insulin stimulation of these amino acid-deprived cells
potently activated Akt (as observed by Akt phosphoryla- ent-mediated signaling through mTOR.
tion on Ser473) but only weakly activated S6K1 (Figure
3, lane 9). Therefore, unlike Rheb-mediated signaling, Rheb Overexpression Specifically Enhances
mTOR-Mediated Signaling to S6K1acute stimulation of PI3K and Akt is not sufficient to fully
activate S6K1 during nutrient insufficiency. The modest To decisively determine whether Rheb positively acti-
vates mTOR signaling, we made use of a rapamycin-insulin-induced activation of S6K1 during amino acid
insufficiency was blocked by wortmannin (Figure 3, lane resistant mutant of S6K1 (S6K1-F5A-CT) [32] (Figure 4).
Unlike treatment with wortmannin, rapamycin treatment11), revealing that this activation is completely depen-
dent on PI3K. Activation of S6K1 upon readdition of was unable to prevent insulin-induced activation of
S6K1-F5A-CT (Figure 4, lane 11), demonstrating thatamino acids (Figure 3, lane 12) was enhanced when
Rheb was overexpressed or when cells were stimulated this mutant is responsive to PI3K signaling but not mTOR
signaling. As a positive control, we coexpressed PDK1with insulin (Figure 3, lanes 13 and 16, respectively).
Interestingly, Rheb-induced S6K1 activation upon read- and PKC, which are known to activate S6K1 through
a PI3K-dependent input [33]. Overexpression of Rhebdition of amino acids was completely inhibited by rapa-
mycin but only partially inhibited by wortmannin (Figure potently activated wild-type S6K1 basally (by 11-fold;
Figure 4, lane 5) and during insulin stimulation (by 17-3, lanes 14 and 15, respectively). In contrast, insulin-
induced S6K1 activity was markedly impaired by both fold; Figure 4, lane 5) but did not enhance the activity
of the S6K1-F5A-CT mutant (Figure 4, lanes 13 and 14).rapamycin and wortmannin. These data convincingly
reveal that Rheb potently activates S6K in the absence In contrast, increased PI3K-mediated signaling toward
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The Tuberin/Hamartin Heterodimer Inhibits Rheb
and Requires the GAP Domain of Tuberin
Previous work revealed that overexpression of wild-type
Rheb led to a significant increase in its activity [27] and
implies that the majority of the overexpressed Rheb
must exist in the active GTP bound form. If this is true,
then the RhebGAP activity must be a limiting factor. If
Tuberin possesses RhebGAP activity, overexpression
of Tuberin should switch Rheb from an active GTP
bound state to an inactive GDP bound state. To indirectly
measure Rheb activity, we analyzed Rheb-induced S6K1
activation within nutrient-deprived HEK293E cells (Fig-
ure 5A). We observed that coexpression of Hamartin and
Tuberin completely blocked Rheb’s ability to activate
S6K1, implying that Tuberin may function as a RhebGAP.
If the GAP domain of Tuberin is essential for Rheb
inactivation, then patient-derived TSC2 GAP domain
point mutants should not block Rheb-induced S6K1 ac-
tivation. To address this, we generated three Tuberin
mutants that mimic patient-derived TSC2 mutations that
occur within the GAP domain and coexpressed these
Tuberin mutants with Hamartin and S6K1. Under serum-
Figure 2. Rheb Induces 4E-BP1 Phosphorylation, which is Rapa- starved conditions, Rheb potently activated S6K1,
mycin Sensitive and Wortmannin Insensitive which was fully blocked by coexpression of wild-type
(A) HEK293E cells expressing Rheb, where indicated, with HA- Tuberin with Hamartin (Figure 5B). In contrast, the three
tagged 4E-BP1 were serum starved. The cells were pretreated with
TSC2 GAP domain point mutants were unable to repress25 nM rapamycin or 100 nM wortmannin for 30 min and then stimu-
Rheb-induced S6K1 activation, revealing that the GAPlated with 100 nM insulin for 30 min, where indicated. The phosphor-
domain of Tuberin is critical for Tuberin’s ability to re-ylation of exogenous 4E-BP1 was determined with an anti-HA anti-
body and phospho-specific antibodies for Ser65 as indicated. The press Rheb-mediated signaling.
, , and  species of 4E-BP1 are labeled accordingly. Rheb and
Akt protein levels as well as Akt phosphorylation on Ser473 were
determined.
Tuberin and Hamartin Act as a GTPase-Activating(B) The cell extracts from Figure 2A were subjected to affinity chro-
Protein Complex toward Rhebmatography on m7GTP-Sepharose, as described in the Experimental
Our in vivo overexpression data strongly suggests thatProcedures. The protein levels of both endogenous eIF4E and HA-
tagged 4E-BP1 were determined. the Tuberin-Hamartin heterodimer inhibits Rheb func-
tion. In order to test whether this is a direct inhibition
due to the GAP activity of Tuberin, we performed in
vitro GAP assays on purified Rheb. We expressed Flag-S6K1 by coexpression of PDK1 and PKC resulted in
significantly enhanced activation of both wild-type S6K1 tagged Hamartin and Flag-tagged Tuberin separately or
together in HEK293 cells and immunoprecipitated the(Figure 4, lanes 7 and 8) and S6K1-F5A-CT (Figure 4,
lanes 15 and 16). These findings strongly suggest that respective protein(s) for use in Rheb-GAP assays. Inter-
estingly, immunoprecipitated Hamartin or Tuberin dis-Rheb induces S6K1 activation via a signaling input that
is upstream of mTOR but not PI3K. played nearly identical GAP activity toward Rheb; both
Figure 3. Rheb Overexpression Enhances
S6K1 Activity in Nutrient-Deprived HEK293E
Cells
HEK293E cells overexpressing Rheb, where
indicated, with S6K1 were serum starved and
nutrient deprived (labeled as “D-PBS”), as de-
scribed in the Experimental Procedures, for
1 hr. Cells were pretreated with either 25 nM
rapamycin or 100 nM wortmannin for 30 min
(where stated) before the readdition of amino
acids (labeled as “PBS  AA”) for 1 hr in the
continued presence of inhibitors. Cells were
stimulated with 100 nM insulin for 30 min,
where indicated. Protein levels of Rheb and
Akt as well as Akt phosphorylation on Ser473
where determined. S6K1 kinase assays were
carried out as for Figure 1. The graphs show
the activity of S6K1 that is standardized to 1
for the untreated sample for each cell medium
used (i.e., DMEM, PBS, and PBS  AA).
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Figure 4. Rheb Overexpression Does Not
Activate the mTOR-Insensitive S6K1 Mutant,
S6K1-F5A-CT
HEK293E cells coexpressing wild-type S6K1
or S6K1-F5A-CT (F5A-CT) with either Rheb
alone or Myc-tagged PDK1 and Flag-tagged
PKC together were serum starved. These
cells were pretreated with either 25 nM rapa-
mycin (Rap) or 100 nM wortmannin (Wort) for
30 min (where stated) prior to being stimu-
lated with 100 nM insulin for 30 min, where
indicated. Protein levels of Rheb, PDK1,
PKC, and Akt as well as Akt phosphorylation
on Ser473 were determined. S6K1 kinase
assays were carried out as for Figure 1. The
activity of wild-type S6K1 and S6K1-F5A-CT
are graphed separately. The serum-starved
controls are standardized to 1 within the
graphs.
enhanced the intrinsic GTPase activity of Rheb (vector) plexes that enhanced Rheb GTPase activity by more
than 100-fold over the activity of either alone and ap-by approximately 2-fold (Figures 6A and 6B). This sug-
gests that a complex between Tuberin and Hamartin is proximately 200-fold over intrinsic Rheb activity (Figures
6A and 6B). This dramatic increase in GAP activity isessential for Tuberin’s GAP activity toward Rheb and
that endogenous levels of coimmunoprecipitating Tu- detected despite no significant difference in the amount
of Tuberin immunoprecipitated when expressed aloneberin or Hamartin are limiting in these reactions. In sup-
port of this, coexpression and immunoprecipitation of or with Hamartin (not shown). Therefore, Tuberin and
Hamartin together form a GTPase-activating proteinboth Tuberin and Hamartin resulted in immune com-
Figure 5. Tuberin-Hamartin Heterodimers Inhibit Rheb and Require the GAP Domain of Tuberin
(A) Rheb was coexpressed in HEK293E cells with HA-tagged S6K1 with or without Hamartin and Tuberin (Ham/Tub), as indicated. These cells
were serum starved (DMEM) and then nutrient deprived (D-PBS) for 1 hr, as for Figure 3. Cells were pretreated with 25 nM rapamycin for 30
min, where indicated. S6K1 kinase assays were carried out as for Figure 1, and an autoradiograph of the gel showing 32P label incorporated
into GST-S6 is presented. The total levels of Hamartin, Tuberin, Rheb, and S6K1 are shown.
(B) HEK293E cells coexpressing Rheb with or without Hamartin (Ham), Tuberin (Tub), and the TSC patient-derived Tuberin mutants (V1571H-
Tub, N1651S-Tub, and N1693K-Tub), as indicated, with HA-tagged S6K1 were serum starved. The samples were analyzed as for Figure 5A.
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Figure 7. Rheb Farnesylation Is Required for Optimal Activation of
S6K1
Wild-type Rheb or a farnesylation-deficient mutant of Rheb (C182S-
Rheb) was coexpressed at four different levels with HA-tagged S6K1
within HEK293E cells that were serum starved. Protein levels of
Rheb (determined with N19 anti-Rheb antibodies) and S6K1 were
determined. S6K1 kinase assays were carried out as for Figure 1.
Fold activation of S6K1 from untreated control is graphed.
To investigate whether farnesylation was important for
Rheb’s ability to activate S6K1, we generated a farnesy-
lation-defective Rheb(C182S) mutant, in which the cys-
teine within the farnesylation CAAX motif is substituted
for a serine. When overexpressed, the Rheb(C182S) mu-
tant was less efficient at enhancing S6K1 activity thanFigure 6. The Tuberin-Hamartin Heterodimer Is a GAP for Rheb
wild-type Rheb (Figure 7). The mutant Rheb(C182S) pro-(A) Tuberin and Hamartin together form a functional Rheb GAP com-
tein migrated as the upper band on SDS-PAGE, whichplex. Flag-Hamartin, Flag-Tuberin, or both were immunoprecipitated
from HEK293 cells and assayed for GAP activity toward purified indicates that it is not being prenylated and is consistent
GST-Rheb (see Experimental Procedures). Shown are [-32P]GTP with earlier studies showing that prenylated Rheb mi-
and GDP eluted from Rheb after a 10 min incubation with the speci- grates more quickly on SDS-PAGE [24]. In contrast, the
fied immune complexes and resolved by one-dimensional thin-layer majority of wild-type Rheb resolved as the lower preny-
chromatography. The ratio of GTP to GDP was determined by phos-
lated band. These findings suggest that the membranephoimager and is given for each assay. GAP activity is seen as a
localization of Rheb through farnesylation is importantdecrease in the GTP-to-GDP ratio relative to vector alone (i.e., intrin-
sic Rheb GTPase activity). for Rheb to efficiently augment mTOR-mediated sig-
(B) Time course of GAP activity toward Rheb. Rheb GAP assays naling.
were performed as described in (A), and the GTP-to-GDP ratio was
determined after 10, 30, and 60 min incubations with the specified Discussion
immune complexes. The graph is given as the log of the GTP-to-
GDP ratio and is normalized to the 0 time point, in which [-32P]GTP-
In this study we show that Rheb functions upstream ofloaded Rheb was incubated on ice with M2-agarose beads.
(C) A patient-derived GAP domain mutant of Tuberin is defective in mTOR within the nutrient signaling pathway. We reveal
Rheb GAP activity. Flag-Tuberin and Flag-TuberinN1651S were as- that Rheb specifically activates mTOR-mediated signal-
sayed for GAP activity toward purified GST-Rheb as described in ing rather than cell signaling through MEK/ERK and
(A), and the resulting GTP-to-GDP ratios are given. PI3K, as shown by Rheb-mediated activation of S6K1
(Figure 1A) but not Akt or RSK1 (Figures 1B and 1C,
respectively). Therefore, it is unlikely that Rheb activatescomplex that greatly enhances the intrinsic GTPase ac-
tivity of Rheb. PI3K and Raf, two downstream effectors of Ras (for
review, see [35]). Rheb has previously been shown toIn order to test if this activity is potentially important
in the prevention of the TSC disease, we compared the interact with Raf in vitro [26], but our data suggest that
Raf is not an effector of Rheb in vivo. Additionally, RhebGAP activity of wild-type Tuberin to that of a patient-
derived mutant mapped to the Tuberin GAP domain overexpression does not increase the activity of the
rapamycin-resistant S6K1 mutant (F5A-CT) that is un-(N1651S). Compared to wild-type Tuberin, the Tu-
berin(N1651S) mutant was greatly reduced in its ability responsive to mTOR signaling inputs but is activated in
response to PI3K signaling (Figure 4). S6K1 activationto enhance Rheb GTPase activity. This suggests that
there is a correlation in the ability of Tuberin to act as is regulated by multiple signaling inputs, one of which
is directed by PI3K. Therefore, these findings are impor-a GAP toward Rheb and its ability to suppress the TSC
disease. tant and confirm that Rheb overexpression specifically
promotes mTOR rather than PI3K signaling. Further-
more, we show that Rheb-induced 4E-BP1 phosphoryla-Rheb Farnesylation Is Required for Optimal
Activation of S6K1 tion is completely sensitive to rapamycin but not to wort-
mannin (Figure 2A), which further strengthens the notionPrevious work has shown that farnesylation of Rheb is
required for cell cycle progression of S. pombe [34]. that Rheb acts upstream of mTOR rather than PI3K. 4E-
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BP1 dissociates from eIF4E upon Rheb overexpression
(Figure 2B), revealing that Rheb-mediated signaling
through mTOR promotes cap-dependent translation.
We also provide evidence that Rheb functions within
the nutrient signaling cascade upstream of mTOR, as
shown by Rheb’s ability to potently stimulate S6K1 activ-
ity during amino acid insufficiency (Figure 3). During
amino acid withdrawal, acute insulin stimulation was
still able to elicit high levels of Akt phosphorylation but
poorly activated S6K1 (Figure 3), showing that the nutri-
ent-mediated mTOR signaling input is essential for opti-
mal S6K1 activation, as previously reported (for review
see [36]). Therefore, Rheb overexpression supersedes
the dependency of the nutrient input to mTOR, sug-
gesting that Rheb is an activator of mTOR within the
nutrient-signaling pathway. Interestingly, resupplying
cells with amino acids further enhanced the activity of
S6K1 when Rheb was overexpressed (Figure 3), sug-
gesting that amino acids may promote the activation of
Rheb. Our research as well as that of others revealed
Figure 8. Model that Illustrates Rheb-Mediated Signaling through
that the Tuberin-Hamartin heterodimer functioned as an mTOR, which Is Inhibited by the TSC Tumor Suppressor Complex
inhibitor of nutrient signaling through mTOR [17–19]. When Rheb is in an active GTP bound state, its localization to the
We show that the Tuberin-Hamartin heterodimer inhibits membrane stimulates mTOR-mediated signaling to downstream
Rheb-induced S6K1 activation during conditions of components S6K1 and 4E-BP1. The TSC tumor suppressor complex
(TSC1/TSC2) acts as a GAP toward Rheb, which promotes hydroly-amino acid withdrawal (Figure 5A). Our work, therefore,
sis of Rheb•GTP, converting it to an inactive GDP bound state.extends these earlier studies revealing that inhibition of
Amino acid-induced signaling activates RhebGEF, which convertsRheb is the mechanism by which the Tuberin-Hamartin
Rheb•GDP to the active Rheb•GTP and promotes mTOR signaling.
heterodimer inhibits nutrient-mediated signaling. Impor- Akt phosphorylates TSC2, which inactivates the TSC tumor suppres-
tantly, the Rheb-inhibitory function of Tuberin-Hamartin sor complex.
heterodimers depends on an intact Tuberin GAP do-
main; patient-derived point mutations within the GAP
[37–39]. Collectively, these papers show that Drosophiladomain of TSC2 prevented the Tuberin-Hamartin het-
Rheb promotes cell growth and proliferation by promot-erodimer from blocking Rheb-induced S6K1 activation
ing dTOR/dS6K1-mediated signaling and that Rheb is(Figure 5B). These data indicate that the GAP activity
a molecular target of dTSC1/2. Epistasis analysis placedof Tuberin promotes inactivation of Rheb in vivo, pre-
Rheb downstream of dTSC1/2 and upstream of dTORsumably through increasing the intrinsic GTPase activity
[37, 38]. In the absence of nutrients, overexpressionof Rheb. Confirming this hypothesis, in vitro Rheb
of Rheb enhanced the growth and proliferation of D.GTPase activity assays revealed that Tuberin enhanced
melanogaster cells [37] and also potently activatedthe intrinsic GTPase activity of Rheb (Figures 6A and
dS6K1 [37, 38]. Work carried out by Zhang et al. also6B). Interestingly, coexpression of Hamartin with Tu-
revealed that TSC2 functioned as a GAP toward Rhebberin markedly enhanced the GTPase activity of Rheb,
and that patient-derived mutations of TSC2 within theimplying that Hamartin promotes the GAP function of
GAP domain prevented TSC2 RhebGAP activity [39].Tuberin toward Rheb. We propose a model whereby
These experiments complement our work revealing thatRheb promotes mTOR signaling when it is in an active
the function of Rheb is conserved between flies andGTP bound form, whereas the Tuberin-Hamartin hetero-
mammals.dimer inhibits Rheb by converting it to an inactive GDP
We further show that Rheb farnesylation is importantbound state (Figure 8). These findings reveal that the
for Rheb to optimally function as an activator of mTORTuberin-Hamartin heterodimer and Rheb respectively
signaling (Figure 7). Supporting our finding, previousinhibit and activate the nutrient-signaling input to mTOR.
reports have shown that Rheb farnesylation is requiredSmall G proteins are additionally regulated by guanine
for cell cycle progression in S. pombe [34] and inhibitionnucleotide exchange factors (GEFs). In our model we
of arginine uptake in S. cerevisiae [24]. Farnesylationpropose that a RhebGEF becomes activated during con-
mediates the membrane localization of many proteinsditions of nutrient sufficiency, and its activation switches
through increased hydrophobicity [40]. Many signalingRheb to an active GTP bound form. Therefore, identi-
components of mTOR are tethered to the membrane.fying this Rheb-GEF will be of great importance and may
For instance, it is likely that Tuberin-Hamartin hetero-provide new insights into how mTOR senses intracellular
dimers are localized to the membrane through the trans-amino acids. However, at this point we cannot rule out
membrane domain of Hamartin [41]. mTOR is also foundthe possibility that Rheb- and nutrient-mediated signal-
within membrane fractions [42]. Therefore, farnesylationing may function in parallel pathways upstream of
of Rheb may recruit Rheb to the mTOR signaling com-mTOR. Further experiments will be carried out to investi-
plex located at the membrane. However, the farnesyla-gate this possibility.
tion-deficient Rheb was still able to activate S6K1 to aUpon preparation of this manuscript, reports charac-
terizing Rheb signaling in D. melanogaster appeared lesser degree than the wild-type when it was expressed
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pCMV6 expressing N-terminal HA-tagged Akt was obtained from P.at higher levels (Figure 7). One explanation for this obser-
Tsichlis (Thomas Jefferson University, Philadelphia, PA).vation is that, during our expression studies, a higher
proportion of Rheb is sufficiently proximal to the mem-
Mammalian Tissue Culture, Transfection,
brane without being farnesylated to activate mTOR sig- and Sample Preparation
naling. The decreased ability of the farnesylation-defi- Human embryonic kidney 293E (HEK293E) cells were cultured (at
cient Rheb to activate mTOR signaling suggests that 37	C within 5% CO2) and maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum. Tran-farnesylation inhibitors might be effective drugs in the
sient transfections were performed by CaPO4 as previously de-treatment of the TSC disease.
scribed [32]. Empty pRK7 was used so that all transfection mixesIt is likely that tumors within TSC patients possess a
contained 6 g of total DNA per 6 cm2 plate. To deprive cells of
higher proportion of the active GTP bound form of Rheb amino acids, we washed the cells once and incubated them with
as a consequence of nonfunctional Tuberin-Hamartin D-PBS containing 1 mg/ml D-glucose (Gibco BRL). To resupply cells
heterodimers. It is also possible that TSC is caused with amino acids, we replaced the media with D-PBS (pH 7.2) (1
mg/ml D-glucose) supplemented with 5
 amino acid solution (MEM,through Rheb mutations that lead to its constitutive acti-
Gibco BRL). eIF4E was purified via affinity chromatography onvation, in a manner analogous to transforming Ras muta-
m7GTP-Sepharose as previously described [20]. After cells weretions of Gln61 [43]. Given that genetic analysis does not
treated, they were washed twice with STE (pH 7.2) buffer and then
always show loss of heterozygosity of either TSC1 or harvested with lysis buffer (10 mM KPO4, 1 mM EDTA, 10 mM MgCl2,
TSC2 within TSC patient lesions [44], it would be impor- 50 mM -glycerophosphate, 5 mM EGTA, 0.5% NP-40, 0.1% Brij
tant to investigate whether these lesions occur as a 35, 1 mM sodium orthovanadate, 40 mg/ml phenylsufonyl fluroride,
10 ug/ml leupeptin, and 5 g pepstatin [pH 7.2]) as previously de-consequence of Rheb mutations. Rheb’s name was de-
scribed [20]. The cell extracts generated were spun at 14,000 rpmrived from the discovery that Rheb was enriched in the
for 10 min and then stored at 80	C.brain [25]. The abundance of Rheb within the brain may
explain why TSC patients preferentially acquire brain
Analysis of Protein Phosphorylation and Association
lesions when compared to lesions in other organs (for of Translation Factors
review see [1]). For Western blotting, lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to nitrocellulose membranes, and blotted with the appropriate anti-Conclusions
body followed by horseradish peroxidase-conjugated secondaryThis work identifies Rheb as a novel molecular target
antibodies. All immunoblots were detected by enhanced chemilumi-
of TSC1 and TSC2 and as an upstream regulator of nescence. Anti-Rheb antibodies (N19 and C19) were purchased from
mTOR-mediated signaling. We show that Rheb overex- Santa Cruz Biotechnology (Santa Cruz, CA). Rheb was detected
with the C19 antibody unless otherwise stated. Anti-Flag antibodiespression potently enhances the activity of S6K1 during
(M2) were purchased from Eastman Kodak Company, New Haven,conditions of nutrient withdrawal. Furthermore, we show
CT. Anti-HA antibodies were kindly provided by M. Chou (Universitythat Tuberin when associated with Hamartin functions
of Pennsylvania, Philadelphia, PA). Anti-4E-BP1 and -Akt antibodiesas a RhebGAP. Additional studies will have to be carried
were supplied by Cell Signaling Technology. Anti-ERK1/2 antibodies
out to characterize the mechanism by which Rheb mod- were generated as previously described [46].
ulates cell signaling through mTOR. Moreover, elucida-
tion of how Rheb functions within the nutrient signaling Immunoprecipitation and Immune Complex Kinase Assays
For immunoprecipitation studies of HA-tagged S6K1, RSK1, andpathway and identification of the RhebGEF will help
Akt, cell extracts were immunoprecipitated with an anti-HA antibodydetermine how mTOR senses the levels of intracellular
bound to protein A-Sepharose (Pharmacia) for 3 hr. Immunoprecipi-amino acids. This study reveals Rheb as a suitable mo-
tates were washed as previously described [47]. For determining
lecular drug target for the treatment of TSC as well as the kinase activity of S6K1 and RSK1 from the washed immunopre-
a key regulatory component of mTOR signaling. cipitates in vitro, recombinant GST-S6 (32 amino acids of the C
terminus) was used as a substrate, as previously described [47].
Experimental Procedures Akt activity assays were determined in vitro with recombinant GST-
tagged GSK-3 that was generated by subcloning of the first 22
Chemicals and Materials amino acids of GSK3 into pGEX-3X (Amersham-Pharmacia) [48].
Wortmannin and U0126 were purchased from BIOMOL Research Quantification of 32P label incorporation was determined with a Bio-
Laboratories, Inc. (Plymouth Meeting, PA), and insulin was bought Rad PhosphorImager and ImageQuant software. All data presented
from Sigma. Epidermal growth factor (EGF) was purchased from in this study are representative of at least three experiments.
Invitrogen (Carlsbad, CA), and radio-labeled ATP[32P] was pur-
chased from NEN Life Science Products (Boston, MA). All other GTPase-Activating Protein Assay
reagents were obtained from VWR Scientific (WestChester, PA), GST-Rheb expressed from pGEX-4T2-Rheb was purified from E.
unless otherwise stated. coli BL21 cells after induction with 50M isopropyl--D-thiogalacto-
pyranoside for 2 hr at 28	C. Bacterial lysates were prepared by
freezing and thawing bacterial pellets in 1/50 volume TNE buffer (50Plasmids
Human Rheb cDNA (bought from ATCC, accession number mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA) plus protease inhibitors
(10 g/ml phenymethylsulfonyl fluoride, 4 g/ml aprotinin, 4 g/mlB1599937) was subcloned into pRK7. The GST-Rheb construct was
made by PCR cloning of the human Rheb cDNA in frame into the leupeptin, and 4 g/ml pepstatin) followed by treatment with DNase
for 10 min on ice. GST-Rheb was then precipitated with glutathioneBamHI and EcoRI sites of pGEX-4T2. pRK7 expressing N-terminal
Flag-tagged Hamartin and Tuberin [19] and N-terminal HA-tagged beads for 1 hr at 4	C, and the beads were washed three times in
Rheb wash buffer (50 mM HEPES [pH 7.5], 0.5 M NaCl, 0.1% Tritonwild-type and F5A-ct S6K1 were generated as previously de-
scribed [32]. pRK7 expressing N-terminal HA-tagged RSK1 was gen- X-100, 5 mM MgCl2, 0.005% SDS plus protease inhibitors), then
once in PBS plus protease inhibitors. Precipitated GST-Rheb waserated as previously described [45]. pACTAG2 expressing human
HA-tagged 4E-BP1 was a kind gift from N. Sonenberg (McGill Univer- then eluted off of the beads with an equal volume of 30 mM glutathi-
one in PBS (pH 7.2) for 1 hr at 4	C. Eluted GST-Rheb was thensity, Montreal, Canada). The Rheb and Tuberin point mutants used
in this study were generated by site-directed mutagenesis according analyzed and quantitated by SDS-PAGE and Coomassie staining of
resolved proteins and BSA standards. This procedure resulted in ato the manufacturer’s instructions (QuikChange; Stratagene).
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concentration of purified GST-Rheb between 0.8 and 1 g/l. This 3. Green, A.J., Smith, M., and Yates, J.R. (1994). Loss of heterozy-
gosity on chromosome 16p13.3 in hamartomas from tuberousGST-Rheb was then used for in vitro GAP assays as described
below. sclerosis patients. Nat. Genet. 6, 193–196.
4. Green, A.J., Johnson, P.H., and Yates, J.R. (1994). The tuberousRheb GAP assays were performed on complexes immunoprecipi-
tated from HEK-293 cells via a modified version of the protocol sclerosis gene on chromosome 9q34 acts as a growth suppres-
sor. Hum. Mol. Genet. 3, 1833–1834.previously described [49]. Lipofectamine PLUS reagents (Invitrogen,
Carlsbad, CA) were used for transfecting HEK 293 cells with pRK7, 5. Ito, N., and Rubin, G.M. (1999). Gigas, a Drosophila homolog of
tuberous sclerosis gene product-2, regulates the cell cycle. CellpRK7-Flag-TSC1, pRK7-Flag-TSC2, or pRK7-Flag-TSC2(N1651S)
on 10-cm culture dishes according to the manufacturer’s instruc- 96, 529–539.
6. Onda, H., Lueck, A., Marks, P.W., Warren, H.B., and Kwiatkow-tions (4 g plasmid DNA per construct per plate). Sixteen hours
after transfection, cells were treated with 100 nM wortmannin for ski, D.J. (1999). Tsc2(/) mice develop tumors in multiple sites
that express gelsolin and are influenced by genetic background.15 min before lysis in 1 ml NP-40 lysis buffer (20 mM Tris [pH 7.4],
150 mM NaCl, 1 mM MgCl2, 1% Nonidet P-40, 10% glycerol, 1 mM J. Clin. Invest. 104, 687–695.
7. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M.,dithiothreitol [DTT], 50 mM -glycerophosphate, and 50 mM NaF,
Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A.,plus protease inhibitors). Flag-tagged proteins were then immuno-
Halley, D., Young, J., et al. (1997). Identification of the tuberousprecipitated for 2 hr with 80 l of an M2-agarose affinity gel slurry
sclerosis gene TSC1 on chromosome 9q34. Science 277,(Sigma-Aldrich Co., St. Louis, MO). Immune complexes on beads
805–808.were then washed three times in IP wash buffer (20 mM HEPES [pH
8. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J.,7.4], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM DTT, 50
Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley,mM -glycerophosphate, and 50 mM NaF, plus protease inhibitors)
D., and van der Sluijs, P. (1998). Interaction between hamartinand once in 1 ml Rheb exchange buffer (50 mM HEPES [pH 7.4], 1
and tuberin, the TSC1 and TSC2 gene products. Hum. Mol.mM MgCl2, 100 mM KCl, 0.1 mg/ml BSA, and 1 mM DTT plus prote-
Genet. 7, 1053–1057.ase inhibitors). The washed beads were then separated into four
9. Lamb, R.F., Roy, C., Diefenbach, T.J., Vinters, H.V., Johnson,aliquots. Three of these were used for separate GAP assays, and
M.W., Jay, D.G., and Hall, A. (2000). The TSC1 tumour suppres-one was resolved by SDS-PAGE and immunoblotted to determine
sor hamartin regulates cell adhesion through ERM proteins andprotein levels. GST-Rheb (10g) was loaded with 100Ci [-32P]GTP
the GTPase Rho. Nat. Cell Biol. 2, 281–287.by incubation for 5 min at 37	C in 100 l GTP-loading buffer (50
10. Wienecke, R., Konig, A., and DeClue, J.E. (1995). IdentificationmM HEPES [pH 7.5], 5 mM EDTA, and 5 mg/ml BSA plus protease
of tuberin, the tuberous sclerosis-2 product. Tuberin possessesinhibitors). After 5 min, 2.5 l 1 M MgCl2, 100 l cold 50 mM HEPES
specific Rap1GAP activity. J. Biol. Chem. 270, 16409–16414.(pH 7.4), and 20 l 10 mM GDP were added to the GTP-loaded Rheb
11. Xiao, G.H., Shoarinejad, F., Jin, F., Golemis, E.A., and Yeung,kept on ice. GAP assays were initiated by the addition of 20 l GTP-
R.S. (1997). The tuberous sclerosis 2 gene product, tuberin,loaded Rheb mixture (approximately 1g GST-Rheb) to each aliquot
functions as a Rab5 GTPase activating protein (GAP) in modu-of M2-agarose immune complexes described above. Assays were
lating endocytosis. J. Biol. Chem. 272, 6097–6100.performed at room temperature with constant agitation for 10, 30,
12. Astrinidis, A., Cash, T.P., Hunter, D.S., Walker, C.L., Chernoff,or 60 min. Reactions were stopped by the addition of 300 l Rheb
J., and Henske, E.P. (2002). Tuberin, the tuberous sclerosiswash buffer containing 1 mg/ml BSA. M2-agarose immune com-
complex 2 tumor suppressor gene product, regulates Rho acti-plexes were removed by brief centrifugation, and nucleotide bound
vation, cell adhesion and migration. Oncogene 21, 8470–8476.GST-Rheb was purified from the supernatant with 20 l glutathione
13. Potter, C.J., Huang, H., and Xu, T. (2001). Drosophila Tsc1 func-bead slurry as described above. After three washes with Rheb wash
tions with Tsc2 to antagonize insulin signaling in regulating cellbuffer, radiolabeled GTP and GDP were eluted from Rheb with 20
growth, cell proliferation, and organ size. Cell 105, 357–368.ul Rheb elution buffer (0.5 mM GDP, 0.5 mM GTP, 5 mM DTT, 5 mM
14. Gao, X., and Pan, D. (2001). TSC1 and TSC2 tumor suppressorsEDTA, and 0.2% SDS) at 68	C for 20 min. Aliquots (1 l) of each
antagonize insulin signaling in cell growth. Genes Dev. 15, 1383–eluted reaction were resolved by thin-layer chromatography on PEI
1392.cellulose (Sigma) with KH2PO4 as the solvent. Relative [-32P]GTP
15. Zhang, H., Stallock, J.P., Ng, J.C., Reinhard, C., and Neufeld,and GDP levels were then detected and quantitated with a phospho-
T.P. (2000). Regulation of cellular growth by the Drosophila tar-imager.
get of rapamycin dTOR. Genes Dev. 14, 2712–2724.
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